bluebird bio, Inc.
BLUEHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $83.8M | $29.1M | $2.7M | $3.7M | $0 | $12.5M |
| Operating income | −$270.5M | −$244.3M | −$250.2M | −$590.9M | −$559.3M | −$563.0M |
| Net income | −$240.7M | −$211.9M | −$230.3M | −$819.4M | −$618.7M | −$789.6M |
| Total assets | $460.2M | $619.2M | $569.8M | $593.8M | $1.78B | $1.73B |
| Total liabilities | $491.8M | $424.6M | $435.5M | $219.5M | $426.2M | $442.4M |
| Equity | −$31.5M | $194.5M | $134.3M | $276.1M | $1.36B | $1.28B |
| EPS (diluted) | $-24.84 | $-38.59 | $-2.93 | $-11.89 | $-9.95 | $-14.31 |
| Shares out. | 193.9M | 106.4M | 71.4M | 67.1M | 55.6M | 55.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −322.8%
- Net margin
- −287.3%
- Return on equity
- 763.4%
- Return on assets
- −52.3%
- Return on capital (ROCE)
- −194.9%
- Liabilities / assets
- 106.9%
- Debt / equity
- —
- Book value / share
- $-0.16
- Revenue growth (YoY)
- 188.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -38.28distress
- Accruals / assets
- 4.2%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 26, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 1, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 30, 2025 | 499,551 | 1.0 | +77.5% |
| May 15, 2025 | 281,482 | 1.0 | -34.3% |
| Apr 30, 2025 | 428,147 | 3.4 | -15.6% |
| Apr 15, 2025 | 507,407 | 1.6 | -71.5% |
| Mar 31, 2025 | 1.8M | 2.6 | -4.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 2, 2025
- Entered a material agreement · Other material eventMay 14, 2025
- Other material eventMar 28, 2025
- Entered a material agreement · Other material eventFeb 21, 2025
- Terminated a material agreementFeb 20, 2025
- Amended charter or bylawsDec 13, 2024
- Shareholder vote · Other material eventDec 4, 2024
- Results of operationsNov 14, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.